NYSE · Healthcare

Lineage Cell Therapeutics, Inc. (LCTX)

As-reported financials and recent SEC filings for Lineage Cell Therapeutics, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.

Snapshot

Revenue

$14.6M

Net income

$-63.5M

Net margin

—

Diluted EPS

$-0.28

ROE

-146.6%

P/E (TTM)

—

Market cap

—

Debt / equity

—

Income statement (as reported)

Line	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	$14.6M	$9.5M	$8.9M	$14.7M	$4.3M
Gross profit	—	—	—	—	$2.9M
Operating income	$-36.6M	$-21.5M	$-24.7M	$-22.5M	$-49.2M
Net income	$-63.5M	$-18.6M	$-21.5M	$-26.3M	$-43.0M
Diluted EPS	$-0.28	$-0.09	$-0.12	$-0.15	—

Source: company XBRL financial statements on SEC EDGAR.

Recent SEC filings

42026-07-02

42026-07-02

42026-07-02

42026-07-02

42026-07-02

42026-07-02

8-K2026-06-12

10-Q2026-05-12

Largest Healthcare peers

UNH

UNITEDHEALTH GROUP INC

All Healthcare companies →

Go deeper on LCTX

Search Lineage Cell Therapeutics, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.

Start free

Or check your whole portfolio free — no account needed.

Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.